Collegium Pharmaceutical (NASDAQ:COLL) – Equities researchers at William Blair raised their FY2019 earnings per share (EPS) estimates for Collegium Pharmaceutical in a report released on Monday, April 16th. William Blair analyst T. Lugo now forecasts that the specialty pharmaceutical company will post earnings of $2.16 per share for the year, up from their prior forecast of $1.97. William Blair currently has a “Outperform” rating on the stock.

How to Become a New Pot Stock Millionaire

COLL has been the topic of a number of other reports. BidaskClub cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, February 23rd. TheStreet upgraded shares of Collegium Pharmaceutical from a “d+” rating to a “c” rating in a report on Wednesday, March 7th. Piper Jaffray set a $33.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a report on Tuesday, January 23rd. Needham & Company LLC lifted their target price on shares of Collegium Pharmaceutical from $28.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Finally, ValuEngine upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $30.83.

NASDAQ:COLL opened at $23.20 on Tuesday. Collegium Pharmaceutical has a fifty-two week low of $7.37 and a fifty-two week high of $29.90. The stock has a market capitalization of $768.10, a PE ratio of -9.39 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.02. Collegium Pharmaceutical had a negative net margin of 262.91% and a negative return on equity of 73.00%. The business had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $9.88 million. The firm’s quarterly revenue was up 728.4% compared to the same quarter last year.

In other Collegium Pharmaceutical news, Chairman Michael Thomas Heffernan sold 20,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $25.01, for a total transaction of $500,200.00. Following the completion of the sale, the chairman now directly owns 535,395 shares in the company, valued at approximately $13,390,228.95. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 25.76% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. purchased a new position in shares of Collegium Pharmaceutical during the 3rd quarter valued at approximately $192,000. Wells Fargo & Company MN increased its holdings in shares of Collegium Pharmaceutical by 12.8% during the 3rd quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock valued at $475,000 after purchasing an additional 5,136 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Collegium Pharmaceutical by 87.5% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after purchasing an additional 3,500 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Collegium Pharmaceutical by 13.5% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 51,119 shares of the specialty pharmaceutical company’s stock valued at $944,000 after purchasing an additional 6,083 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at approximately $176,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

TRADEMARK VIOLATION WARNING: “William Blair Comments on Collegium Pharmaceutical’s FY2019 Earnings (COLL)” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2018/04/17/william-blair-comments-on-collegium-pharmaceuticals-fy2019-earnings-coll.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.